Renaissance Capital logo

Virax Biolabs Group Priced, Nasdaq: VRAX

UK-based provider of diagnostic tests and PPE for viral diseases.

Industry: Health Care

Latest Trade: $5.54 0.00 (0.0%)

First Day Return: +264.0%

Return from IPO: +10.8%

Industry: Health Care

We are a holding company incorporated as an exempted company under the laws of the Cayman Islands. As a holding company with no material operations of our own, we conduct our substantial operations in the United Kingdom and Hong Kong with operating subsidiaries in Singapore, China and British Virgin Islands and have been operating since 2013. We are a global innovative biotechnology group that primarily engages in sales, distribution and marketing of diagnostics test kits and med-tech and Personal Protective Equipment (“PPE”) products for the prevention, detection, diagnosis and risk management of viral diseases with a particular interest in the field of immunology. Our mission is to minimize the risks of viruses throughout the world via our products offerings. Our product portfolio includes: (i) diagnostics test kits sold through our “ViraxClear” brand; (ii) med-tech and PPE products sold through our “ViraxCare” brand; and (iii) sourced brands of third party suppliers, independent of our own brands (“Sourced Brands”). We also expect to launch an upcoming brand “Virax Immune”, with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against major global viral diseases.
more less
IPO News for Virax Biolabs Group
more
IPO Data
IPO File Date 03/18/2022
Offer Price $5.00
Price Range $5.00 - $5.00
Offer Shares (mm) 1.4
Deal Size ($mm) $7
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 07/20/2022
Offer Price $5.00
Price Range $5.00 - $5.00
Offer Shares (mm) 1.4
Deal Size ($mm) $7
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters London, United Kingdom
Founded 2013
Employees 6
Website www.viraxbiolabs.com